Swedish Ibrance Registries Insights (SIRI)

Study acronym: SIRI
StatusCompleted
PhaseNot specified
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Secondary endpoints: details revised at 1 of 2 entries
    • Site details revised
    • Eligibility criteria expanded, about 2 words
  2. Trial status: Active, Not Recruiting to Recruiting
    • Primary and study completion dates: Dec 31, 2025 to May 31, 2026
    • Site details revised
    v6
  3. Primary and study completion dates: Aug 31, 2024 to Dec 31, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study site revised
    v5
  4. Primary and study completion dates: Dec 31, 2022 to Aug 31, 2024v4
  5. Primary and study completion dates: Mar 31, 2021 to Dec 31, 2022v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 30, 2020 to Dec 15, 2020
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
441 trials monitored
See 30 trials at risk
Breast Cancer
5,481 trials monitored
See 311 trials at risk
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
Trial Details
NCT Number NCT04654208
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Malignant Neoplasm of Breast
Related terms Breast Neoplasms
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov